The Life Sciences team advised SixPeaks Bio in its acquisition by AstraZeneca for a total potential consideration of up to $300 million. The transaction includes an upfront payment of $170 million, $30 million payable in two years, and up to $100 million tied to future regulatory milestones. The acquisition, which closed in late October, supports AstraZeneca's strategic focus on developing next-generation obesity treatments that prioritize muscle preservation alongside weight reduction.
SixPeaks Bio is developing a pipeline of best- and first-in-class medicines for healthy weight loss. The company emerged from Versant Ventures' Ridgeline Discovery Engine in the Basel Technology Park.
The Goodwin deal team was led by Robert Puopolo and Andrew Harrow, supported by Michael Grainger, Hattie Muncey, Amine Assouad, Heidi McNally and Matthew Lee, with licensing assistance from Morag Peberdy, Kathleen Kean, Christopher Zhong and Lucy Sharples, anti-trust advice from Arman Oruc, Kevin Walsh and Andrew Jensen and tax advice from Dan Karelitz, Dulcie Daly and Nathan Langford.